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ABSTRACT 
Stem cell therapy (SCT) is a promising and 
prospective approach in the treatment of pa-
tients with severe peripheral arterial disorders, 
primarily with Buerger’s disease. However, very 
little is known about the duration of the effect of 
SCT, and to our best knowledge no data are 
available on the efficacy and safety of repeated 
SCT in patients with Buerger’s disease. Here we 
report on two patients with severe Buerger’s 
disease, who received repeated autologous 
bone marrow-derived stem cell therapy. Our 
results show that a second SCT, applied to a 
previously treated leg 30 or 36 months after the 
first treatment was efficient in both cases. After 
twelve months, the clinical state of the repeat-
edly treated lower limb improved spectacularly 
and non-healing ulcers healed more rapidly 
than after the first SCT. No severe adverse 
events were detected. Thus repeated SCT offers 
a safe and efficient treatment option for relaps-
ing patients at the advanced stage of Buerger’s 
disease. 
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1. INTRODUCTION 
Recent publications have proved the efficacy and 
safety of stem cell therapy (SCT) in patients with severe 
Buerger’s disease [1-14]. However, very little informa-
tion is available on the duration of the beneficial effect 
of SCT [12], and according to our best knowledge no 
data exist on the efficacy and safety of repeated SCT 
carried out in patients with relapsing or worsening clini-
cal states in severe Buerger’s disease. Here we report on 
two cases, where the lower limb of patients with Buer-
ger’s disease, previously treated by autologous bone 
marrow-derived stem cell therapy (ABMSCT) [9], have 
been re-treated with freshly isolated autologous bone 
marrow derived isolated CD34+ cells. Both patients re-
lapsed at 30 - 36 months after the first ABMSCT. As 
they responded to the first treatment, we decided to re-
peat ABMSCT with freshly isolated bone marrow de-
rived CD34+ cells by using the same method as de-
scribed in our previous publication [9]. 
2. MATERIALS AND METHODS 
As it is a repeated stem cell therapy we refer to our 
previous publication [9]. 
3. RESULTS 
3.1. Case Reports 
Patient 1 was a 59-year-old man with Buerger’s dis-
ease since 1976. He had rest pain, 50 m walking distance 
without pain, and 2 large (8 cm2) and deep non-healing 
ulcers on both feet. He had sympathectomy on both sides 
(1982, 1983). Amputation of the right toe II and left toe I 
was carried out in 1991, and the amputation of the left 
toe III was done in 1995. Disease stage was Ler-
ishe/Fontain-IV before ABMSCT. As his left lower limb 
was in a worse condition, we treated it by ABMSCT in 
August 2006. The clinical state of this limb is still ex-
cellent (rest pain disappeared, the ischaemic ulcer healed 
and has not relapsed so far), whereas the clinical state of 
the untreated right limb became worse (rest pain in-
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creased, the ischaemic ulcer got larger and deeper). In 
April 2007 ABMSCT was carried out on his right foot 
(Figure 1 (a)) and nine months later we observed sig-
nificant improvement of the treated right foot (Figure 1 
(b)). In October 2009, 30 months after the second SCT 
the condition of his right limb relapsed with a large and 
deep ischaemic ulcer at the same place (Figure 1 (c)). 
His good response to previous treatments prompted us to 
repeat ABMSCT on his right foot. Twelve months after 
the repeated treatment, a significant improvement was 
observed both in the general angiological state of the 
limb and in the size of the ischaemic ulcer (Figure 1 
(d)). 
Patient 2 was a 40-year-old man with Buerger’s dis-
ease since 1991. He had rest pain, < 50 m walking dis-
tance without pain, and a large and deep non-healing 
ulcer (36 cm2) on his left foot. He had sympatectomy on 
both sides (1994 and 1995). He underwent amputations 
of his left toe I-III and right toe I-II (1994), and left fin-
ger III (1999). Disease stage was Lerishe/Fontain-IV 
before ABMSCT. SCT was given in September 2006 
 
 
(a)                          (b) 
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Figure 1. Repeated ABMSCT in a patient (D. A. 59 ys) with 
severe Buerger’s disease. (a) Before first ABMSCT, (b) 9 
months after first ABMSCT, (c) Relapse, 30 months after 
first ABMSCT, D: 6 months after second ABMSCT. 
(Figure 2 (a)) and after l2 months the clinical state of 
the treated limb improved significantly as the non-heal- 
ing ulcer healed and rest pain disappeared (Figure 2 (b)). 
In October 2009, 36 months after SCT a large and deep 
ischaemic ulcer re-appeared just at the same place as 
before (Figure 2 (c)). Taken his previous clinical re-
sponse to therapy, we repeated ABMSCT and six 
months after the treatment we detected complete healing 
of the ischaemic ulcer (Figure 2 (d)). Simultaneously 
the symptoms in the limb improved significantly. 
4. DISCUSSION 
Amputation is the only option for relief of rest pain or 
large and deep ischaemic ulcers in patients with severe 
Buerger’s disease. No effective blood-flow enhancement 
therapies are available for these patients. ABMSCT is a 
promising and prospective approach in the treatment of 
severe peripheral arterial disorders, in particular in 
Buerger’s disease. All of the published clinical trials 
have reported on the affectivity and safety of ABMSCT 
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Figure 2. Repeated ABMSCT in a patient (F.T. 40 ys) with 
severe Buerger’s disease. (a) before first ABMSCT, (b) after 
12 months of first ABMSCT, (c) relapse, 36 months after 
first ABMSCT, (d) 6 months after second ABMSCT. 
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in Buerger’s disease even though the variation of the cell 
populations and protocols used for the therapy [1-16]. 
It is well established that the bone marrow contains 
multiple stem- and progenitor cells with the potential to 
support vessel regeneration. As we proposed previously 
[9], when these cells interact with tissue- and immune 
cells in the inflammed milieu of the obstructed vessel, 
they very likely acquire novel activities and trigger a 
cascade of local events that support vasculogenesis and 
wound healing. These complex mechanisms may in-
volve controlled production of soluble factors, regulation 
of endothelial cell functions, formation of new vessels, 
tissue regeneration, and inhibition of inflammation 
[17,18]. These events altogether may support increased 
blood flow, healing of ischaemic ulcers and ultimately 
protect the leg from amputation. 
Recently, Fadini et al. collected clinical data of 700 
patients with peripheral arterial disorders treated by SCT 
[15]. In patients with thromboangiitis obliterans (TAO) 
showed larger benefits from SCT than patients with 
atherosclerosis obliterans (ASO). The survival rate and 
amputation-free state were markedly better in patients 
with TAO than those in patients with ASO (100% vs. 
80% and 91% vs. 60%). This metaanalysis indicates that 
intramuscular introduction of autologous stem cells is a 
feasible, safe and effective therapeutic strategy for pa-
tients with severe peripheral arterial disorders (PAD) 
[15]. Currently 22 phase I-III clinical trials, using 
ABMSCT in advanced ASO and TAO are going on. The 
results of these trials will provide with important infor-
mation for the final consideration of stem cell therapy in 
these diseases [15]. 
Very little information is available on the long term 
effects of SCT that requires the clinical follow up of the 
patients for years [12]. Furthermore, there are no clinical 
data on the effects of repeated SCT neither in TAO nor 
in ASO. Here we report on two patients with severe 
Buerger’s disease who received repeated ABMSCT. In 
both cases, the relapse occurred 30 - 36 months after the 
first SCT. After six months of the repeated treatment 
however, the clinical state of the treated limbs improved 
considerably, the non-healing ulcers healed more rapidly 
than during the first SCT without any severe adverse 
events. Based on these observations we conclude that 
repeated ABMSCT is safe and effective even in settings 
of repeated treatments. 
Stem cell therapy carried out on the left lower limb of 
our first patient demonstrates an excellent clinical re-
sponse to the therapy with duration of almost 4 years, 
despite its worse condition as compared to the right leg. 
Although SCT was performed with the same technique 
on both legs, the right limb relapsed 30 months after the 
treatment. We do not have a definite explanation for the 
clinically different local responses of this patient to the 
therapies performed at different time points, but it may 
depend on the actual composition of the functionally 
relevant stem- and progenitor cells. The quality control 
of the autologous bone marrow-derived stem- and pro-
genitor cell suspensions performed as detailed in our 
previous publication [9] revealed that no major differ-
ences in the ratios of CD34+ and CD34+CD133+ sub-
populations of the cell fractions used for the therapy 
could be detected. 
Remarkably, the large and deep ischemic ulcers ap-
peared in both cases at the same place as for the first 
time. This observation points to a transient and incom-
plete regeneration process of vessels. Nevertheless, our 
present results clearly show that relapsed cases of Buer-
ger’s disease can be treated by repeated ABMSCT with 
high efficacy without adverse events. 
5. CONCLUSION 
Stem cell therapy is a promising and prospective 
novel approach in the treatment of patients with severe 
Buerger’s disease. In two cases the lower limb of pa-
tients with Buerger’s disease previously treated by 
ABMSCT have been re-treated with freshly isolated 
autologous bone-marrow derived CD34+ cells. Both pa-
tients relapsed at 30 - 36 months after the first ABMSCT. 
Our present results clearly show that relapsed cases of 
advanced Buerger’s disease can be treated by repeated 
ABMSCT with high efficacy without adverse events. 
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